Pemphigus Vulgaris (PV)-Epidemiology Forecast–2030

Pemphigus Vulgaris (PV)-Epidemiology Forecast–2030

  • September 2020 •
  • 100 pages •
  • Report ID: 5962309 •
  • Format: PDF
‘Pemphigus Vulgaris (PV)-Epidemiology Forecast–2030’ report delivers an in-depth understanding of the PV, historical and forecasted epidemiology as well as the PV trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Pemphigus Vulgaris (PV) Disease Understanding
Pemphigus Vulgaris (PV) is defined as a potentially fatal, autoimmune and intraepithelial disease characterized by flaccid blisters, and erosions of the skin and mucous membrane. It is histologically marked by acantholysis and is mediated by circulating desmoglein-reactive autoantibodies, directed against keratinocyte cell surfaces.
PV is subdivided into two subtypes: mucosal-dominant type and mucocutaneous type. The mucosal-dominant type of PV shows blisters mainly and erosive lesions on the oral mucosa while mucocutaneous type also shows flaccid bullae and intractable erosions of the skin. PV is further segmented based on the severity of the disease as mild, moderate and severe.
Pemphigus Vulgaris (PV) Epidemiology Perspective
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent Population of PV, Gender-specific Diagnosed Prevalent Population of PV, Severity-specific Diagnosed Prevalent Population of PV, and Age-specific Diagnosed Prevalent Population of PV scenario of PV in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2017 to 2030.
Pemphigus Vulgaris (PV) Detailed Epidemiology Segmentation
• The increasing geriatric population and rising prevalence of PV generates a large patient population in the 7MM. In 2017, the diagnosed prevalent population of PV in the 7MM was 41,217.
• The United States contributes the largest share with 13,526 cases in 2017 acquiring near about 32.81% of the totals 7MM share. On the other hand, EU5 and Japan account for 60.10% and 7.09% diagnosed prevalent population share respectively in 2017.
• A female predominance in PV is well established. However, the genetic and physiological basis for this gender bias is not well understood. In 2017, males and females contribute to 5,275 and 8,251 diagnosed prevalent cases in the US.
• Epidemiology model for PV estimates that out of the total diagnosed prevalent population of 13,526 cases in the US for PV in 2017, 5,814 cases are of mild, 3,678 cases are of moderate, and 4,034 accounted for severe cases, respectively.
• The majority of the PV cases were found in adults between 60–70 years of age. In 2017, 3,014 cases, 2,449 cases, were contributed by patients age 60–69 years, 70–79 years, and lowest cases observed in the age-group of 0–17 years (406 cases) in 2017, respectively in the US.

Scope of the Report
• The report covers the descriptive overview of PV, explaining its causes, signs and symptoms, and pathophysiology.
• The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
• The report assesses the disease risk and burden and highlights the unmet needs of PV.
• The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
• The report provides the segmentation of the disease epidemiology for 7MM by Total Diagnosed Prevalent Population of PV, Gender-specific Diagnosed Prevalent Population of PV, Severity-specific Diagnosed Prevalent Population of PV, and Age-specific Diagnosed Prevalent Population of PV.

Report Highlights
• 11-Year Forecast of PV
• 7MM Coverage
• Total Diagnosed Prevalent Population of PV
• Gender-specific Diagnosed Prevalent Population of PV
• Severity-specific Diagnosed Prevalent Population of PV
• Age-specific Diagnosed Prevalent Population of PV

Key Questions Answered
• What is the disease risk, burden and unmet needs of PV?
• What is the historical PV patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
• What would be the forecasted patient pool of PV at the 7MM level?
• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to PV?
• Out of the above-mentioned countries, which country would have the highest prevalent population of PV during the forecast period (2020–2030)?
• At what CAGR the population is expected to grow across the 7MM during the forecast period (2020–2030)?

Reasons to buy
The PV report will allow the user to -
• Develop business strategies by understanding the trends shaping and driving the 7MM PV epidemiology forecast.
• The PV epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
• The PV epidemiology model developed is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the eleven-year forecast period using reputable sources.

Key Assessments
• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Geographies Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
Study Period: 2017–2030